Top Funds' Activity in Q4 2023

Lisa Kalai Han and Pia Singh of CNBC report Dow slides more than 100 points Friday, major averages end 5-week winning run:

Stocks slid Friday after yet another hot inflation report stoked fears that Federal Reserve rate cuts may not arrive until later than anticipated this year.
The S&P 500 fell 0.48% to end at 5,005.57, and the Dow Jones Industrial Average slid 145.13 points, or 0.37%, settling at 38,627.99. The Nasdaq Composite lost 0.82% to finish at 15,775.65.
All three major indexes broke their five-week winning streaks to end the week in the negative. The S&P 500 ended the week lower by 0.42%, while the Dow slipped 0.11%. The Nasdaq tumbled 1.34%.
The producer price index for January, a measure of wholesale inflation, increased 0.3%. Economists polled by Dow Jones had anticipated a gain of 0.1%. Excluding food and energy, core PPI rose increased 0.5%, higher than the expectations for a 0.1% advance.
The 10-year Treasury yield spiked above 4.3% following the hot PPI reading. At one point, the 2-year Treasury yield topped 4.7%, the highest since December.
It’s been a roller-coaster week for stocks, with investors carefully assessing the direction of the U.S. economy and when the Federal Reserve may decide to lower rates. On Tuesday, the Dow posted its biggest daily decline in nearly a year after January’s headline consumer price index reading came in at 3.1%, higher than the 2.9% economists polled by Dow Jones were expecting.
The market shook off the report the next two days, with the S&P 500 rebounding on Thursday to close at yet another record high. But Friday’s wholesale inflation report added to concerns the Fed may have to wait until later in the year before it starts cutting rates.
Greg Bassuk, chief executive officer at AXS Investments, told CNBC that investors should brace for more near-term volatility ahead. Until recently, most investors were confident “that rate cuts would start in the first half of the year, and it’s looking more likely that the Fed will delay until the second half,” he said.
Bassuk added: “The seesaw market is really reflective of this tug-of-war between high sticky inflation — which suggests no near-term rate cuts — and strong earnings and other signs of a robust economy, which underscores investors belief that there’s more growth ahead for stocks.”
Applied Materials popped 6% Friday on stronger-than-expected earnings. Shares of food delivery service DoorDash dropped 8% on a wider-than-expected loss, while digital advertising company Trade Desk popped about 17% after topping analysts’ fourth-quarter revenue estimates and offering an upbeat outlook for the first quarter.

It's that time of the year again where we get a sneak peek into the portfolio's of the world's most famous money managers.

Before I get to it, it was a volatile week as inflation reports hit stocks and yields popped:

Still, I wouldn't read too much into the latest inflation reports except to say there's still some stickiness and it remains to be seen if this will persist.

But the Fed's inflation gauge is the PCE deflator and Fed Chair Jerome Powell explicitly stated they are not waiting for inflation to drop to 2% to start cutting rates.

Having said this, the stock market is incredibly concentrated in a few names and the risks of something bad hitting us are on the rise right now, which is why you should all take these 13F filings with a grain of salt here.

S&P 500 is the most concentrated it’s been in 50 years and is approaching an all-time high. This is fine right? pic.twitter.com/17sGoSfLRn
— Barchart (@Barchart) February 15, 2024

Moreover, the risk of a recession is rising, which never augurs well for risk assets:

🟥WARNING🟥

The yield curve is steepening rapidly.

We should face a full-blown recession by the end of this year. pic.twitter.com/DDEi4jcuFJ
— HZ (@MFHoz) February 16, 2024

ALERT: Median home prices are now contracting at levels NEVER seen in 60 years

This is truly a historic moment pic.twitter.com/h5IveWfE5G
— Game of Trades (@GameofTrades_) February 16, 2024

BEWARE: Trucking employment collapse has been a precursor to recessions since 1991 pic.twitter.com/4zFU1K1H9Y
— Game of Trades (@GameofTrades_) February 17, 2024

And to make matters worse, some people state financial conditions are looser now than when the Fed started raising rates and Lawrence Summers thinks there's a 15% chance the Fed's next move is to raise,not cut rates:

Financial conditions today are easier than when the Fed started raising interest rates in March 2022.

As seen in the chart below, financial conditions today are actually near their best since January 2022.

The same picture can be seen in measures of financial conditions from… pic.twitter.com/Xo6CtbUsdT
— The Kobeissi Letter (@KobeissiLetter) February 16, 2024

There’s a meaningful chance — maybe it’s 15% — that the next move is going to be upwards in rates, not downwards. The @federalreserve is going to have to be very careful.

Watch my interview w @DavidWestin tonight 6pm ET @BloombergTV Wall Street Week.https://t.co/QIPp9Rc68j…
— Lawrence H. Summers (@LHSummers) February 16, 2024

Needless to say, if the Fed is forced to raise rates instead of cutting them, it's going to hit risk assets and the economy very hard.

All this to say the macro backdrop is poor and deteriorating fast and concentration risk is at extremes in the stock market, so take everything you read about what gurus bought and sold below with a shaker, not grain of salt.

Also keep in mind, the data is lagged by 45 days and doesn't include short positions or options.

Top Funds' Activity in Q4 2023

Alright, let's get into it.

David Hollerith of Yahoo Finance reports Amazon, Alphabet, and Nvidia attract new interest from Wall Street's biggest investors:

Some of Wall Street’s biggest investors made new bets on technology giants in the fourth quarter, loading up on stakes in Amazon (AMZN), Alphabet (GOOG, GOOGL), Alibaba (BABA), and Nvidia (NVDA).
Warren Buffett’s Berkshire Hathaway (BRK), however, did not. The conglomerate trimmed its holdings in Apple (AAPL) and HP (HPE) while adding to its stakes in oil giants Chevron (CVX) and Occidental Petroleum (OXY). There was at least one additional investment Berkshire kept confidential for now.
The details about these new bets made in the fourth quarter emerged this week in a series of filings to the Securities and Exchange Commission. Large institutional investors are required to make these disclosures on a quarterly basis, showing what they bought and sold.
What the latest batch showed is that many piled into tech names at the end of 2023.
A hedge fund run by Michael Burry — who famously shorted subprime mortgages during the 2008 financial crisis and became a central figure in Michael Lewis’s 2010 book "The Big Short" — added 35,000 shares of Alphabet and 30,000 shares of Amazon. That fund, Scion Capital, also boosted bets on Chinese e-commerce giants Alibaba and JD.com.
Many hedge funds also gravitated to the stock of Nvidia, the dominant artificial intelligence chipmaker.
Bridgewater Associates, the world’s biggest hedge fund firm, increased its stake in Nvidia by 458% as it added more than 220,000 shares.
It also increased its position in Alphabet by more than 465,000 shares, making it the fund’s 12th-largest position as of the end of December, and added a small stake in Apple.
Another hedge fund, AQR, increased its stake in Nvidia by 22%. But it trimmed its holdings in Apple and Microsoft, its two largest positions, by 5% and 4%, respectively.
Berkshire sold just 1% of its holdings in Apple, or 10 million shares, leaving it with a huge stake of more than 950 million shares.
Apple has had a rough start to 2024 as it juggled downgrades to its stock price, major changes to its App Store policies, and a potential antitrust lawsuit that could target large swaths of its business. These challenges mounted as it launched the ambitious Vision Pro headset.
One other notable investor pared back its exposure to Apple in the fourth quarter: the Soros Fund.
The outfit started by billionaire investor George Soros and now run by his son closed out a short position and zeroed out of its underlying holdings in the tech giant.
Some of these same investors made some notable bets on the banking industry, especially a regional lender that is currently under a lot of scrutiny: New York Community Bank (NYCB).
The Soros Fund, AQR, and Millennium Management all increased their exposure to NYCB, which surprised Wall Street on Jan. 31 by slashing its dividend and reporting a net quarterly loss of $252 million.
It is not known what these funds did with their stakes between the end of the fourth quarter and now.

My immediate thoughts after reading this is why the hell are big hedge funds buying the parabolic move in Nvidia:

I know why, these are momentum strategies which go long large cap megacap tech stocks as long as price is above the one-month moving average (they make it sound sophisticated but trust me, it isn't).

Nvidia reports next week and if you believe Loop Capital's price target, it still has 65% upside from these insanely lofty levels:

Nvidia $NVDA will hit $1,200 says Loop Capital pic.twitter.com/ppjzFWFsDZ
— Barchart (@Barchart) February 16, 2024

Of course, god forbid the company disappoints investors because it will suffer the same fate as Roku Inc today or far worse given it's priced for perfection:

And it wasn't just Roku.Earlier this week, shares of Twilio Inc, another high-flyer from the past, got clobbered after delivering less than stellar results:

Will Nvidia disappoint investors next week and bring about a major selloff in tech?

Maybe but this company has ripped the face off short sellers so I wouldn't bet on it.

All I know is it can easily fall below it 50-day moving average in a blink of an eye IF it disappoints:

Alright, let's look at what other stocks top hedge funds bought last quarter, courtesy of Bill Arpert of Barron's who took an inside peek:

If you are a serious investor, your sweetheart was likely mad at you on Valentine’s Day. That’s because you were studying the 14,000 different investment positions that hedge fund giant Citadel Advisors had at year-end.
Every Feb. 14, big money managers are required to file 13F forms with the U.S. Securities and Exchange Commission, revealing many of their Dec. 31 holdings. Among the notable new buys at the largest hedge funds were names like Walt Disney, Micron Technology, and Oracle.
The field’s best investment results in recent years have been those of “multistrategy” hedge funds like Ken Griffin’s Citadel and Izzy Englander’s Millennium Management. Their consistent, strong returns might make poring over their13Fs seem like a tempting way to ride their coattails without paying their steep management fees.
Beware. The high-turnover, complex strategies of the multi-strat shops make their 13Fs the hardest to interpret on all of Wall Street.
With some $60 billion managed by dozens of teams, Citadel’s December-quarter 13F discloses positions worth hundreds of billions of dollars in the aggregate, thanks to leverage. To analyze Citadel’s changes, and those of other multistrats, we went to the website 13F.info operated by the data scientist Todd Schneider.
Over 680 of Citadel’s year-end positions exceeded $100 million apiece. Many of the largest were market bets made with exchange-traded funds like the SPDR S&P 500, which multistrats use to keep their overall portfolio from rising or falling with the market’s tide.
Citadel’s largest reported bets on common stocks were, unsurprisingly, the large-cap stocks Nvidia, Microsoft, and Amazon.com. From September to December, the fund’s 13Fs show a tripling of its Amazon shareholdings, a roughly 75% boost in Nvidia, and about a 15% reduction in Microsoft. But the fund’s bets on stocks aren’t confined to common shares.
Along with its shareholdings, Citadel had put and call option bets on those three names, and many others in its portfolio. The reported value of Citadel’s bearish and bullish options on those three big names actually exceeded its stock positions. The option reporting in a 13F is almost uninterpretable, noted the financial-data expert Byrne Hobart in his blog last year, because the entries only show the total value controlled by the options—not their dates or strike prices.
And 13Fs include no information at all on short sales or swap trades. That mean that the real size and direction of a hedge fund’s bet on a stock can be the opposite of what its 13F might suggest, Hobart explained.
More informative moves in a multistrat’s 13F might be the really, really big share purchases. Among Citadel’s $100 million bets, about 30 increased by 1,000% or more between the September and December filings, including common holdings of Citigroup, Caterpillar, and Visa. Again, there were options bets on all three whose notional value exceeded the size of the common stock positions—but the overall direction on three names all appeared to be bullish. At least they were on Dec. 31.
Among its big positions, there were smaller-cap stocks in which Citadel’s December quarter increases were even more dramatic. Its shareholdings in chip-designer software supplier Synopsys, security software vendor Dynatrace, and the genetic testing firm Natera each jumped by more than 50,000% from the end of September.
Millennium is the other multistrat firm whose assets under management exceed $60 billion. Its December 13F showed about 400 positions over $100 million each.
A dozen of those big Millennium’s shareholdings jumped by more than 1,000% in the quarter. The largest-cap names in that bunch were health insurer Cigna Group, the retailer TJX Cos., industrial gas supplier Linde, and casualty insurer Progressive. Shareholdings in Progressive jumped almost 48,000%, with only a very modest offsetting options hedge. The big purchases of Cigna, Linde, and TJX shares were also offset by relatively small opposing options bets.
The very biggest jumps in shareholdings at Millennium included smaller names like the British heating and plumbing supplier Ferguson, the regional bank Webster Financial, eBay, and the data-analysis software supplier Palantir Technologies.
D.E. Shaw is the big quant shop that’s quietly put up one of the best long-term records. Among its $100 million-plus positions, the December 13F reveals a 3,500% jump in Shaw’s holdings of chip maker Micron Technology, with a relatively small offsetting option hedge. Holdings in Netflix stock rose some 670%, also with only a smallish negative options hedge. The fund’s shareholdings of Chipotle Mexican Grill grew nearly 1,000% in the quarter, but were accompanied by sizable opposing options positions.
Somewhat smaller multistrategy managers that nevertheless have wide followings are Steve Cohen’s Point72 Asset Management and Nicholas Maounis’ Verition Fund Management. Their 13Fs seem to point in clearer directions than those of larger firms.
Point72 reported about 90 positions exceeding $100 million in its December filing. New and largely unhedged bets appeared on the energy giants Shell and Exxon Mobil. New software bets included Oracle and HubSpot. Other new or greatly increased positions included Clorox, defense firm General Dynamics, chemical giant 3M, home builder Lennar, biotech firms Immunovant and Repligen, and United Airlines Holdings.
The hedge fund Verition is smaller still, but showed about 20 positions above $50 million each in its December 13F. Those with more than a 1,000% increase in shareholdings, and seemingly modest options hedges, included Disney, the utility NextEra Energy, Google parent Alphabet, the videogame publisher Electronic Arts, and the weight-loss drug leader Eli Lilly.
It’s important to remember that the multistrat firms avoid big drawdowns by being fleet on their feet—so the 45-day old snapshot in their 13Fs may be dated before it appears.
These filings are no shortcut to market-beating performance, or “alpha,” the data maven Hobart warns, because the better-known a money manager is, the more people are studying its 13Fs.
The information found in a 13F should only be the starting point of any investor’s research.

Yeah, multistrategy funds are churning their portfolio or doing other trades you don't see to hedge them, so it's difficult to read too much into their trading.

Below, I provide a detailed list of top hedge funds, you click on the link, see their top holdings, then click on column (change %) twice to see where they increased their holdings the most.

For example, below look at the top holdings of Viking Global, a top L/S fund (note that Nvidia doesn't figure among the fund's top 20 holdings, they played Advanced Micro Devices instead, another high-flyer):

Then click on the column with heading change% which I circled below (click twice to get largest percentage change in positions):

You will see Viking Global increased its stake in the insurer The Progressive Coporation (PGR) by 400% in Q4 and that stock has continued to run up nicely in Q1:

Would I buy it here? Probably not but these are the type of breakouts smart traders buy.

Now, at the bottom of Viking Global's largest percentage increase table above, you will see shares of a biotech company Viking Therapeutics:

These shares have performed extraordinarily well since Q4, almost quadrupling in price.

Biotech is a space I track very closely. This is where I see the greatest risks and opportunities.

For example, I can tell you all about Viking Therapeutics and other companies treating NASH and obesity like Madrigal Pharmaceuticals (MDGL), Terns Pharmaceuticals (TERN) and Sagimet Biosciences (SGMT).

These stocks swing like crazy and in biotech, you have to know what top biotech funds are buying and more importantly, when to buy the big dips and when to sell the big rips.

Today, Sarepta Therapeutics said that the US FDA would review an application seeking traditional approval for its gene therapy to treat a muscle-wasting disorder by June 21, months after it failed the main goal of a confirmatory trial, and shares rallied:

Among the top holders, you'll see Avoro Capital, one of many top biotech funds I track closely.

After the close today, shares of Iovance (IOVA) rallied 34%:

Why did it rally? Because the FDA granted an accelerated approval for its cell therapy for adult patients with advanced melanoma, the first such treatment to be approved for the deadliest form of skin cancer.

The agency's greenlight for the first cell therapy targeting a solid tumor allows use in patients who have been previously treated with other therapies, but their cancer has spread to other parts of the body, and cannot be removed with surgery.
Lifileucel, branded as Amtagvi, is a tumor derived immunotherapy composed of a patient's own disease-fighting white blood cells known as T-cells, with a specific type called tumor-infiltrating lymphocytes (TIL).
Amtagvi will be sold in the U.S. at a list price of $515,000 per patient, interim CEO Frederick Vogt said on a conference call.
The accelerated approval of Amtagvi is based on safety and effectiveness data from a global study of 73 patients. The therapy will require confirmatory trials to receive the U.S. Food and Drug Administration's traditional approval.
"The potential market for TIL therapy is sizable, as 90% of all cancers are solid tumors compared to 10% as blood cancers," Dr. Jason Bock, co-founder and CEO of Cell Therapy Manufacturing Center, said.
The study data showed the objective response rate, a measure of treatment effectiveness, in patients treated with Amtagvi at the recommended dose, was 31.5%.
"With approval in hand, the company has a scarce wholly-owned asset and would make a nice tuck-in for big pharma who could leverage this even better," brokerage Jefferies analyst Michael Yee said in a note.
The therapy's label comes with a boxed warning for treatment-related mortality, prolonged severe cytopenia, severe infection, and cardiopulmonary and renal impairment.
Vogt said the company does not see the boxed warning having any impact on sales and expects to begin reporting significant revenue in the second quarter of this year.
"TIL therapy offers a promising option for patients with solid tumors," Bock said, adding "CAR-T or other cell therapies have so far not shown great success in treating these cancer types."
Iovance is also conducting a late-stage trial to confirm clinical benefits of the therapy.

Interestingly, news broke out of FDA approval 20 minutes before market close, shares declined and then rallied after the bell (this is biotech, weird stuff always goes on in biotech).

Anyway, among the top holders of Iovance, you'll find Avoro again and Perceptive Advisors, another top biotech fund I track closely.

Biotech is where you'll find the biggest disruptors of tomorrow but also the biggest risks as it's fraught with risks and very volatile.

I can write books on some of the biotechs I've traded including Avoro's top holding, Apellis Pharmaceuticals which gave me heartburn last year when I bought that massive dip and it kept falling before finally recovering nicely (patience was key there):

That's the nature of the biotech beast, it ain't for the faint of heart, that's for sure!

Alright, it's late Friday evening and I want to watch Shark Tank which I'm taping and hit the sack.

As always, please remember to support this blog by donating via PayPal on the top left-hand side under my picture. Thank you!!

Below, have fun looking into the portfolios of the world's most famous money managers and other top funds.

The links below take you straight to their top holdings and then click to see where they increased and decreased their holdings (see column headings).

Top multi-strategy, event driven hedge funds and large hedge fund managers

As the name implies, these hedge funds invest across a wide variety of hedge fund strategies like L/S Equity, L/S credit, global macro, convertible arbitrage, risk arbitrage, volatility arbitrage, merger arbitrage, distressed debt and statistical pair trading. Below are links to the holdings of some top multi-strategy hedge funds I track closely:

1) Appaloosa LP

2) Citadel Advisors

3) Balyasny Asset Management

4) Point72 Asset Management (Steve Cohen)

5) Millennium Management

6) Farallon Capital Management

7) Shonfeld Strategic Partners

8) Walleye Capital

9) Verition Fund Management

10) Peak6 Investments

11) Kingdon Capital Management

12) HBK Investments

13) Highbridge Capital Management

14) Highland Capital Management

15) Hudson Bay Capital Management

16) Pentwater Capital Management

17) Sculptor Capital Management (formerly known as Och-Ziff Capital Management)

18) ExodusPoint Capital Management

19) Carlson Capital Management

20) Magnetar Capital

21) Whitebox Advisors

22) QVT Financial

23) Paloma Partners

24) Weiss Multi-Strategy Advisors

25) York Capital Management

Top Global Macro Hedge Funds and Family Offices

These hedge funds gained notoriety because of George Soros, arguably the best and most famous hedge fund manager. Global macros typically invest across fixed income, currency, commodity and equity markets.

George Soros, Carl Icahn, Stanley Druckenmiller, Julian Robertson have converted their hedge funds into family offices to manage their own money.

1) Soros Fund Management

2) Icahn Associates

3) Duquesne Family Office (Stanley Druckenmiller)

4) Bridgewater Associates

5) Pointstate Capital Partners

6) Caxton Associates (Bruce Kovner)

7) Tudor Investment Corporation (Paul Tudor Jones)

8) Tiger Management (Julian Robertson)

9) Discovery Capital Management (Rob Citrone)

10 Moore Capital Management

11) Rokos Capital Management

12) Element Capital

13) Bill and Melinda Gates Foundation Trust (Michael Larson, the man behind Gates)

Top Quant and Market Neutral Hedge Funds

These funds use sophisticated mathematical algorithms to make their returns, typically using high-frequency models so they churn their portfolios often. A few of them have outstanding long-term track records and many believe quants are taking over the world. They typically only hire PhDs in mathematics, physics and computer science to develop their algorithms. Market neutral funds will engage in pair trading to remove market beta. Some are large asset managers that specialize in factor investing.

1) Alyeska Investment Group

2) Renaissance Technologies

3) DE Shaw & Co.

4) Two Sigma Investments

5) Cubist Systematic Strategies (a quant division of Point72)

6) Man Group

7) Analytic Investors

8) AQR Capital Management

9) Dimensional Fund Advisors

10) Quantitative Investment Management

11) Oxford Asset Management

12) PDT Partners

13) Angelo Gordon

14) Quantitative Systematic Strategies

15) Quantitative Investment Management

16) Bayesian Capital Management

17) SABA Capital Management

18) Quadrature Capital

19) Simplex Trading

Top Deep Value, Activist, Growth at a Reasonable Price, Event Driven and Distressed Debt Funds

These are among the top long-only funds that everyone tracks. They include funds run by legendary investors like Warren Buffet, Seth Klarman, Ron Baron and Ken Fisher. Activist investors like to make investments in companies where management lacks the proper incentives to maximize shareholder value. They differ from traditional L/S hedge funds by having a more concentrated portfolio. Distressed debt funds typically invest in debt of a company but sometimes take equity positions.

1) Abrams Capital Management (the one-man wealth machine)

2) Berkshire Hathaway

3) TCI Fund Management

4) Baron Partners Fund (click here to view other Baron funds)

5) BHR Capital

6) Fisher Asset Management

7) Baupost Group

8) Fairfax Financial Holdings

9) Fairholme Capital

10) Gotham Asset Management

11) Fir Tree Partners

12) Elliott Investment Management (Paul Singer)

50) Oaktree Capital Management

51) Fayez Sarofim & Co

18) Bridger Capital Management

19) Boxer Capital

20) Omega Fund Management

21) Bridgeway Capital Management

22) Cohen & Steers

23) Cardinal Capital Management

24) Munder Capital Management

25) Diamondhill Capital Management

26) Cortina Asset Management

27) Geneva Capital Management

28) Criterion Capital Management

29) Daruma Capital Management

30) 12 West Capital Management

31) RA Capital Management

32) Sarissa Capital Management

33) Rock Springs Capital Management

34) Senzar Asset Management

35) Paradigm Biocapital Advisors

36) Sphera Funds

37) Tang Capital Management

38) Thomson Horstmann & Bryant

39) Ecor1 Capital

40) Opaleye Management

41) NEA Management Company

42) Sofinnova Investments

39) Ariel Investments

40) ARK Investment Management

Canadian Asset Managers

Here are a few Canadian funds I track closely:

1) Addenda Capital

2) Letko, Brosseau and Associates

3) Fiera Capital Corporation

4) West Face Capital

5) Hexavest

6) 1832 Asset Management

7) Jarislowsky, Fraser

8) Connor, Clark & Lunn Investment Management

9) TD Asset Management

10) CIBC Asset Management

11) Beutel, Goodman & Co

12) Greystone Managed Investments

13) Mackenzie Financial Corporation

14) Great West Life Assurance Co

15) Guardian Capital

16) Scotia Capital

17) AGF Investments

18) Montrusco Bolton

19) CI Investments

20) Venator Capital Management

21) Van Berkom and Associates

22) Formula Growth

23) Hillsdale Investment Management

Pension Funds, Endowment Funds, Sovereign Wealth Funds and the Fed's Swiss Surrogate

Last but not least, I the track activity of some pension funds, endowment, sovereign wealth funds and the Swiss National Bank (aka the Fed's Swiss surrogate). Below, a sample of the funds I track closely:

1) Alberta Investment Management Corporation (AIMco)

2) Ontario Teachers' Pension Plan

3) Canada Pension Plan Investment Board

4) Caisse de dépôt et placement du Québec

5) OMERS Administration Corp.

6) Healthcare of Ontario Pension Plan (HOOPP)

7) British Columbia Investment Management Corporation (BCI)

8) Public Sector Pension Investment Board (PSP Investments)

9) PGGM Investments

10) APG All Pensions Group

11) California Public Employees Retirement System (CalPERS)

12) California State Teachers Retirement System (CalSTRS)

13) New York State Common Fund

14) New York State Teachers Retirement System

15) State Board of Administration of Florida Retirement System

16) State of Wisconsin Investment Board

17) State of New Jersey Common Pension Fund

18) Public Employees Retirement System of Ohio

19) STRS Ohio

20) Teacher Retirement System of Texas

21) Virginia Retirement Systems

22) TIAA CREF investment Management

23) Harvard Management Co.

24) Norges Bank

25) Nordea Investment Management

26) Korea Investment Corp.

27) Singapore Temasek Holdings

28) Yale Endowment Fund

29) Swiss National Bank (aka, the Fed's Swiss surrogate)

Below, Jay Woods, Freedom Capital Markets chief global strategist, joins 'Squawk Box' to discuss the key takeaways from the latest 13F filings, latest market trends, and more.

Next, John Kolovos, Macro Risk Advisors chief technical market strategist, joins 'Closing Bell' to discuss why he believes there will be further market correction and his top sector picks.

Third, Eric Rosengren, Former Boston Fed president, joins 'Closing Bell Overtime' to talk the FOMC's next move, what's in store for the bond market, the state of the economy and more.

Fourth, former US Treasury Secretary Lawrence Summers says that persistent inflationary pressures evident in the latest data suggest that there’s potential for the next Federal Reserve policy move to be to raise interest rates, not lower them. He speaks with David Westin on "Wall Street Week."

Lastly, the FDA has just approved a new kind of therapy for a deadly form of skin cancer. It's a treatment using a patient's own cells and it could transform the future of treating advanced tumors. NBC's Anne Thompson reports.

Search This Blog

Pension Pulse

Top Funds' Activity in Q4 2023

Comments

Post a Comment